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Abstract
Cardiovascular diseases continue to be a major cause of
mortality and morbidity in the world population. First
open heart procedure was performed by Gibbon in 1953,
since then many advancements have been introduced to
the field of cardiac surgery. Minimally invasive techniques
were introduced, which include minimally invasive
coronary artery bypass grafting (CABG), off-pump
technique, minimally invasive valve surgery or
transcatheter techniques to implant stentless or
sutureless valves. The hybrid strategy to address coronary
disease combines catheterisation procedures with
standard surgical techniques. Cardiac imaging has also
progressed to provide three-dimensional images of the
heart, enabling surgeons to plan procedures with greater
accuracy. Left ventricular assist devices can be used in
patients suffering from cardiogenic shock or awaiting
heart transplantation. Total artificial heart can be used for
biventricular mechanical support. As technology
becomes increasingly used for patient management, the
future surgeon needs to be trained in minimally invasive
surgical techniques.
Keywords: Cardiovascular diseases, Cardiac surgery,
Minimally invasive surgery, Cardiac catheterization.
Introduction
Cardiovascular disorders continue to be the leading
cause of mortality and disability across all age groups
throughout the world. The World Health Organisation
(WHO) expects this burden of disease to increase in the
coming years in the developing world. Prevention and
medical treatment continue to be mainstay of treatment
and disease prevention and limitation. With
advancements in technology, newer options for
treatment have become available. This review aims to
summarise these options.
History of Modern Cardiothoracic Surgery
In 1953, Gibbon successfully performed an open-heart
procedure using a heart lung machine, which worked on
the principle of extracorporeal oxygenation; this
pioneered the modern-day techniques used in
cardiothoracic surgery. The 1960s saw the advent of usage
of internal mammary artery and saphenous venous grafts
on a heart with ischemic arrest, to bypass the
artheroscelerotic coronary vessels.
Minimally Invasive Cardiac Surgery
With the birth of minimally invasive cardiothoracic
surgery (MICS), the term minimally invasive coronary
artery bypass grafting (MICABG) was introduced. This
includes modifications in the visualisation techniques,
myocardial stabilisation, "off-pump" and port-access
CABG (PACAB), techniques of harvesting internal
mammary artery, radial artery and saphenous veins,
alternatives to vascular anastomosis, and device-
supported myocardial revascularisation. This includes
access to the heart through smaller incisions for
valvular and congenital heart deformities. Off-pump
technique is made possible by use of stabilisation
devices, which allow localised stabilisation to
facilitatate anastamosis.1 With the advent of MICS, the
patient satisfaction increased as pain was reduced,
cosmesis became better, and recovery was faster.
MICS can be performed through a J or an L shaped
partial sternotomy or through the third or the fourth
intercostal space on the right side. Robotic Da Vinci
system also came to be used for MICS for performing
totally endoscopic coronary artery bypass grafting
(TECAB) and to perform valve repairs. The 1990s saw
the initiation of minimally invasive mitral valve
surgery (MIMVS) and minimally invasive direct
coronary artery bypass (MIDCAB) also known as the
off-pump coronary artery bypass grafting (OPCABG),
the latter is performed through anterolateral
thoracotomies with no usage of cardio-pulmonary
bypass (CBP). Other examples of MICS include
minimally invasive aortic valve (MIAVR) and minimally
invasive atrial fibrillation ablation. Transcatheter valve
replacement or repair has also been in use for the
replacement or repair of mitral (with a mitraclip) or
aortic valve though percutaneous intervention, also
known astranscatheter aortic valve implantation
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(TAVI). Transcatheter mitral valve repair or
replacement is also being performed.2 Suture less or
rapid deployment aortic valves are also becoming
popular for implantation through minimally invasive
techniques.3 Stentless bioprosthetic valves were also
introduced in the 1990s to optimise hemodynamics,
reduce stress along the valve, to increase its
durability. They are primarily used to replace the
aortic valve.4 Thoracic and abdominal aortic
aneurysms may also be repaired using endovascular
stent grafts through a minimally invasive technique.
This is known as thoracic endovascular aneurysm
repair (TEVAR).5 Angioplasties and stenting of carotid,
renal, visceral and peripheral arteries can also be
achieved.
Hybrid Cardiac Operating Room
The hybrid strategy to address coronary artery disease
(CAD) combines catheterisation procedures with standard
operating surgical techniques. Anastamosis of left internal
mammary artery (LIMA) is performed with the left
anterior descending artery (LAD) with minimally invasive
or open technique. Percutaneous coronary intervention
(PCI) procedure is then used to catheterise non-LAD
occluded vessels.6 Other procedures include PCI in
combination with minimally invasive valve surgery such
as MIAVR, hybrid atrial fibrillation abalation with
epicardial and epicardial approach and for repair of
complex thoracic aortic aneurysms. Hybrid operating
room (OR) has high-quality imaging available, which
incudes a multiplane angiography machine, the ability to
change the OR table for open surgery, transesophageal
echo, OR lighting, laminar air flow and anaesthesia and
heart lung machine (Figure-1).6
Advances in Cardiac Imaging: 3-D Modeling
and Printing
Cardiac imaging has become an integral facet in
diagnosing and managing cardiac diseases. Images from
echocardiography, computed tomography (CT) and
magnetic resonance imaging (MRI) can now be integrated
to provide a 3-D image of the heart, or 3-D computational
image. This will aid the cardiothoracic surgeons greatly in
preoperative planning, decision-making and
management of their patients. The 3-D printing is an
increasingly popular clinical tool and this technology can
bioprint customised valves and grafts for cardiac surgical
procedures. It can also be used for building patient-
specific realistic models for surgical planning, education
and training of young surgeons. Three-dimensional
transesophageal echocardiography is also in use, which
provides better estimations of left ventricular function.
This allows for better preoperative planning and
evaluation of postsurgical repair.7
Stem Cells for Treatment of Heart Failure:
Cardiosphere-Derived Cells
Contrary to previous belief, the human heart has the
ability to repair itself. Recent trials also bring resident
cardiosphere derived cells (CDCs) into the limelight as a
possible management for heart failure, as they exert a
cardioprotective effect on the heart. Use of autologous
cells from the body solves the problem of rejection. A
phase I clinical trials using endogenous stem cell
population isolated directly
from the heart has shown a
significant improvement in
cardiac function and patient
outcome over a 1- to 2-year
trial period in patients of
heart failure. Cardiosphere-
Derived autologous stem
Cells to reverse ventric Ular
dysfunction (CADUCEUS)
trial established that
injection of CDCs into the
infarct artery following a
myocardial infarction (MI)
showed noteworthy
increase in viable heart
tissue, reduction of scar,
increase in regional
contractility and systolic
wall thickening, but the left
ventricular end diastolic
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Figure-1: Hybrid OR.
volume, end systolic volume and ejection fraction
(LVEF) did not differ significantly from the control group
in 6 months. While the SCIPIO trial tested the use of c-kit
cells from the CDCs in patients with heart failure of
ischemic aetiology, and found significant increase in
LVEF after infusion of c-kit cells following the surgery
through percutaneous intervention.8 More trials are
underway to tap into the endogenous ability of the
heart to heal itself as patients with heart failure
continue to grow (Figure-2).
Bridging the Gap to Transplantation: Left
Ventricular Assist Devices and
Extracorporeal Membrane Oxygenation
Left ventricular assist devices (LVAD) have greatly
increased the survival rates of patients suffering from
cardiogenic shock awaiting heart transplantation.
Extracorporeal membrane oxygenation (ECMO) is also
a viable option for patients with respiratory failure and
in cardiogenic shock to provide emergency circulatory
support. ECMO followed by LVAD provide a sustained
bridge to ultimate heart transplantation. LVAD cater to
population of patients that remain refractory to
maximal medical therapy for heart failure. Although
this device significantly lowers the morbidity and
mortality associated with heart failure, but sepsis
continues to be a major threat after device
implantation as well as haemolysis, need for
anticoagulation and limited battery life. Impella is a
type of ventricular assist device (VAD)which is used in
patients with severe heart failure and in cardiogenic
shock.9 Implantation of a total artificial heart (TAH) can
also be used in patients in need of a biventricular
mechanical support as a bridge to transplant or as a
destination therapy.10
Implications for Education and Training of
Future Surgeons
As technology and automation become increasingly
used for patient management, the future surgeon
needs to be trained in minimally invasive surgical
options. We foresee a greater emphasis in the future on
dry and wet labs and simulation models to impart
training and evaluation of surgical techniques to the
surgeons of the future.
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